Genocea Biosciences Inc (GNCAQ)

[micromillionaire]

Analysts Set Genocea Biosciences, Inc. (GNCA) Price Target at $7.47

Posted by Stefani Robinson on Oct 22nd, 2017

Genocea Biosciences logoShares of Genocea Biosciences, Inc. (NASDAQ:GNCA) have received a consensus rating of “Buy” from the eight brokerages that are presently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and five have issued a buy recommendation on the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $7.47.

A number of equities research analysts recently commented on GNCA shares. Needham & Company LLC upgraded shares of Genocea Biosciences from a “hold” rating to a “buy” rating and set a $12.00 price objective for the company in a research report on Monday, July 24th. Zacks Investment Research downgraded shares of Genocea Biosciences from a “hold” rating to a “sell” rating in a research report on Friday, August 11th. Cowen and Company restated an “outperform” rating and issued a $40.00 price objective on shares of Genocea Biosciences in a research report on Tuesday, July 25th. ValuEngine downgraded shares of Genocea Biosciences from a “sell” rating to a “strong sell” rating in a research report on Tuesday, September 26th. Finally, Piper Jaffray Companies reiterated an “overweight” rating and set a $18.00 price target (up from $17.00) on shares of Genocea Biosciences in a research report on Tuesday, July 25th.

In other news, CFO Jonathan Poole sold 45,000 shares of the firm’s stock in a transaction that occurred on Monday, July 24th. The shares were sold at an average price of $6.00, for a total transaction of $270,000.00. Following the completion of the transaction, the chief financial officer now directly owns 84,247 shares of the company’s stock, valued at approximately $505,482. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Company insiders own 6.70% of the company’s stock.

Several institutional investors and hedge funds have recently modified their holdings of GNCA. GSA Capital Partners LLP purchased a new position in shares of Genocea Biosciences during the 2nd quarter worth approximately $100,000. Ameriprise Financial Inc. increased its stake in shares of Genocea Biosciences by 11.5% during the 2nd quarter. Ameriprise Financial Inc. now owns 22,233 shares of the biotechnology company’s stock worth $119,000 after purchasing an additional 2,300 shares in the last quarter. State of Wisconsin Investment Board purchased a new position in shares of Genocea Biosciences during the 2nd quarter worth approximately $125,000. Rhumbline Advisers purchased a new position in shares of Genocea Biosciences during the 2nd quarter worth approximately $157,000. Finally, New York State Common Retirement Fund purchased a new position in shares of Genocea Biosciences during the 2nd quarter worth approximately $159,000. 59.25% of the stock is owned by institutional investors and hedge funds.

Shares of Genocea Biosciences (GNCA) traded up 4.29% during trading on Thursday, hitting $1.46. The company had a trading volume of 763,900 shares. The firm’s market capitalization is $41.79 million. Genocea Biosciences has a 52-week low of $1.13 and a 52-week high of $7.29. The stock’s 50-day moving average is $3.24 and its 200 day moving average is $4.97.

Genocea Biosciences (NASDAQ:GNCA) last announced its quarterly earnings data on Wednesday, August 9th. The biotechnology company reported ($0.54) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.46) by ($0.08). Equities research analysts predict that Genocea Biosciences will post ($1.92) earnings per share for the current fiscal year.


https://www.truebluetribune.com/2017/10/22/analysts-set-genocea-biosciences-inc-gnca-price-target-at-7-47.html